AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01989078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Adults and Children >50 kg:~* Those with systolic blood pressure (SBP) ≥ 100 mm Hg at entry will start with 50 mg of oral losartan once daily. At the week 2 visit, losartan will be increased to 100 mg daily.~* Those with SBP \<100 mm Hg at entry will start with 25 mg of oral losartan once daily. Participants will return after 1 week for titration to 50 mg daily, if tolerated (i.e. SBP not lower than pre-losartan measurement by 10 mm Hg or more), and after 2 weeks to monitor blood pressure.~Children \<50 kg weight:~* Treatment will start with 25 mg oral Losartan once daily given as a morning dose. At the 2 week visit, Losartan will be increased to 50 mg daily. The dose will be increased to 100 mg once a body weight of 50 kg is achieved.
Study NCT01244724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
Study NCT01327105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TVU
Description: Use of transvaginal ultrasound to determine location of micro-insert
Study NCT04184869 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Belinostat
Description: Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Belinostat Dose Cohort A \& B: 1000mg/m2 Belinostat Dose Cohort C: 750mg/m2 Frequency: once cycle of 21 days: cycle 1, Day 1 and Cycle1, Day 2 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up.
Study NCT04184869 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir
Description: Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir) Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up.
Study NCT01332474 — intervention group
Intervention type: DRUG
Intervention: BOTOX
Description: BOTOX
Study NCT03547739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Self-testing
Description: Women in this study group will receive oral-fluid-based rapid HIV test kits for themselves and their male partner at up to 4 time points (twice during pregnancy and twice postpartum). Each test will be accompanied with a self-testing instruction sheet describing step-by-step procedures in multiple languages. Study staff will also conduct a brief demonstration on how to use the tests. Participants will be encouraged to offer a test kit to their male partner or to undertake couples testing. They will also be counseled on how to talk to their partners and the possibility of adverse partner reactions. Participants will be instructed to seek clinic-based confirmatory testing if a reactive self-test result is obtained.
Study NCT03688165 — intervention group
Intervention type: DEVICE
Intervention: Treadmill-based Robotic Gait Training
Description: All the stroke survivors admitted to the participating centers and eligible for the study will follow a gait training protocol (treadmill-based or overground). The data will be registered at baseline (T0), end of treatment (T1) and at three months follow up (T2). All robotic systems used for the study (Lokomat Pro - Hocoma AG, Volketswil, Switzerland); G-EO System - Reha technologies, Italy) are treadmill-based and do not provide the over-ground gait training. They are characterized by the possibility of a programmable weight support, as well as speed and stride length. The data relating to the patients' training is always displayed and stored with a computerized control system.
Study NCT03932227 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cardioskin
Description: Subjects will have a 24h recording with Cardioskin, next will be unequipped.
Study NCT03932227 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Holter
Description: Subjects will have a 24h recording with Holter, next will be unequipped.
Study NCT03776383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic use feedback letter
Description: Mailed letters indicating that the physician prescribes more antibiotics than 75% of their peers
Study NCT03569774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-lung ventilation with low PEEP
Description: Subjects will receive one-lung ventilation with low PEEP (5 cmH2O)
Study NCT02520674 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: optic nerve head ophthalmoscopy
Description: Patients underwent undilated smartphone ophthalmoscopy followed by undilated slit-lamp biomicroscopy for the grading of the vertical cup-to-disc ratio of the optic nerve head.
Study NCT01338792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01338792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT01338792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01338792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01338792 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study NCT01338792 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study NCT02989194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS410 low dose
Description: Single intravenous fixed low dose of VIS410
Study NCT02989194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS410 high dose
Description: Single intravenous fixed high dose of VIS410
Study NCT02989194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous infusion of placebo
Study NCT05533021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and Consultancy
Description: In order to facilitate the transition to motherhood, theory-based training and counseling was provided to primiparous mothers on self and infant care.
Study NCT02696473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carrot
Study NCT03712150 — intervention group
Intervention type: DEVICE
Intervention: tdcs
Description: application of optimised parameters of tDCS (anodal stimulation, 1.5 mA, 10 min) over the unconditioned hemisphere reverses the brain and behavioural consequences of inhibitory pre-conditioning
Study NCT02944123 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel 75 mg
Description: Clopidogrel 600 mg as loading dose followed by 75 mg/day as maintenance dose.
Study NCT01063608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-H1N1v Vaccine
Description: Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan.
Study NCT04607304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABCA2 GIRMS
Description: Two systems (ABCA-C and ABCA-D) with run order randomized
Study NCT01775579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage SR tablet 750 mg, Crestor tablet 20 mg
Study NCT01405352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: 25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month
Study NCT01405352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: 25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month
Study NCT02936310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Living With Stress
Description: The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.
Study NCT01516580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
Description: Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses.
Study NCT02944123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg
Description: Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
Study NCT02944123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 45 mg
Description: Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
Study NCT03074032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC1-0013B
Description: ONC1-0013B per os daily
Study NCT01488656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7-pill placebo dietary packed visually identical to active dietary supplement
Study NCT01488656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant, anti-inflammatory dietary supplement
Description: A combination of dietary supplements including: β-carotene, vitamin C, vitamin D3, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, calcium, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, boron, silicon, vanadium, eicosapentaenoic acid, docosahexaenoic acid, olive extract, mixed tocopherols, bioflavonoids, inositol, choline, N-acetyl L-cysteine, bromelain, coenzyme Q10, turmeric extract, lutein, lycopene, broccoli concentrate, grape seed extract
Study NCT03206060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177-DOTATATE
Description: Lu-177-DOTATATE IV at weeks 1, 8, 16 and 24.
Study NCT03206060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-DOTATATE
Description: Ga-68-DOTATATE PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
Study NCT03206060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18-FDG
Description: F-18-FDG PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
Study NCT03206060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acid solution
Description: AA solution will be administered 60 minutes prior to each Lu-177-DOTATATE infusion.
Study NCT02624050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methohexital
Description: Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
Study NCT02624050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
Study NCT04189146 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Inner Engineering Intervention
Description: The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony.
Study NCT04733183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
Study NCT04733183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
Study NCT04733183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onfekafusp alfa
Description: L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day
Study NCT01019343 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial direct current stimulation involves the application of weak direct currents, delivered between two surface electrodes, placed over the scalp.
Study NCT01019343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial direct current stimulation involves the application of weak direct currents, delivered between two surface electrodes, placed over the scalp.
Study NCT01019343 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Eye-tracking Device
Description: The purpose of this device is to assess eye movement. Participants may sit down in front of a computer screen or a real-world environment, stand on a treadmill, or lie down in an MRI scanner. Small infrared cameras attached to the cap or glasses will be positioned in front of their eyes. Eye tracking might be performed alone, or in conjunction with EEG, EMG, fMRI or treadmill. The eye- tracking device is FDA approved and commercially available.
Study NCT01019343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye-tracking Device
Description: The purpose of this device is to assess eye movement. Participants may sit down in front of a computer screen or a real-world environment, stand on a treadmill, or lie down in an MRI scanner. Small infrared cameras attached to the cap or glasses will be positioned in front of their eyes. Eye tracking might be performed alone, or in conjunction with EEG, EMG, fMRI or treadmill. The eye- tracking device is FDA approved and commercially available.
Study NCT01019343 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pulsed vibrator
Description: This device would be used in experiments to see if gait can be improved and, if so, what parameters of stimulation are optimal.
Study NCT01019343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed vibrator
Description: This device would be used in experiments to see if gait can be improved and, if so, what parameters of stimulation are optimal.
Study NCT01019343 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gait Trainer Treadmill (GTT)
Description: The Gait Trainer is a specialized rehabilitation treadmill, which operates in both the forward and backwards mode allowing subjects to both train and undergo performance tasks in a relatively safe and expedient manner. The GTT is equipped with a mounted deck with built in sensors which monitors and records subjects gait speed, step length, right to left time distribution, and symmetry in real time in both forward and reverse modes.
Study NCT01019343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait Trainer Treadmill (GTT)
Description: The Gait Trainer is a specialized rehabilitation treadmill, which operates in both the forward and backwards mode allowing subjects to both train and undergo performance tasks in a relatively safe and expedient manner. The GTT is equipped with a mounted deck with built in sensors which monitors and records subjects gait speed, step length, right to left time distribution, and symmetry in real time in both forward and reverse modes.
Study NCT01019343 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scales MMSE and MOCA
Description: Scales of motor function, cognitive function and psychiatric function are valuable supplements to clinical assessments of patients, giving quantitative information concerning these different aspects of brain function. Selected scales would be used only when potentially useful in a sub-study where such quantitative information would be correlated with a physiological or imaging result.
Study NCT01019343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scales MMSE and MOCA
Description: Scales of motor function, cognitive function and psychiatric function are valuable supplements to clinical assessments of patients, giving quantitative information concerning these different aspects of brain function. Selected scales would be used only when potentially useful in a sub-study where such quantitative information would be correlated with a physiological or imaging result.
Study NCT01019343 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: iMobility
Description: This test uses the iMobility system. iMobility Device is a small device designed to measure movement through sensors (test monitors) worn by a patient via Velcro straps around an ankle or wrist or worn as a pendant around the neck to lie over the sternum. The device is a nonsignificant risk device.The iMobility Device has been used before, in the same format with a similar paradigm, in previous NIH studies.
Study NCT01019343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iMobility
Description: This test uses the iMobility system. iMobility Device is a small device designed to measure movement through sensors (test monitors) worn by a patient via Velcro straps around an ankle or wrist or worn as a pendant around the neck to lie over the sternum. The device is a nonsignificant risk device.The iMobility Device has been used before, in the same format with a similar paradigm, in previous NIH studies.
Study NCT01019343 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: QMAT
Description: The purpose of this study is to assess the ability of the QMAT (quantitative motor assessment tool) to assess slowness of movement associated with Parkinson Disease. The QMAT device is FDA approved and has been used before, in the same format with a similar paradigm, in previous NIH studies.
Study NCT01019343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QMAT
Description: The purpose of this study is to assess the ability of the QMAT (quantitative motor assessment tool) to assess slowness of movement associated with Parkinson Disease. The QMAT device is FDA approved and has been used before, in the same format with a similar paradigm, in previous NIH studies.
Study NCT01019343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill Test
Description: Subjects will be fitted in a weight support harness for safety. Sensors will be placed on the subject s shoes and harness. The sensors (VICON system) will be used to record their stride length, position and velocity as they walk on a treadmill. This system is a motion-tracking system that is designed to measure various aspects of a person s gait.
Study NCT01640951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 150 mg
Description: (1 injection per dose) and placebo to Secukinumab 150 mg
Study NCT01640951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 300 mg
Description: Secukinumab 150 mg (2 injections per dose)
Study NCT01019343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Test
Description: Subjects will be fitted in a weight support harness for safety. Sensors will be placed on the subject s shoes and harness. The sensors (VICON system) will be used to record their stride length, position and velocity as they walk on a treadmill. This system is a motion-tracking system that is designed to measure various aspects of a person s gait.
Study NCT01019343 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Arm Intellistretch Device
Description: The purpose of the Arm Intellistretch device is to objectively quantify wrist tone. It is used for rehabilitation applications in hospitals and office settings. Currently, rigidity is evaluated clinically using a subjective scale, zero to four and is part of the UPDRS. The Arm Intellistretch device is manufactured by Rehabtek, Inc., is FDA approved, and has been determined to be a non-significant risk device by the CNS IRB.
Study NCT01516580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
Description: LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).